Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 13 h ago

CRESCENT BIOPHARMA, INC.: BIOTECHNOLOGY VALUE FUND L P amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Biotechnology Value Fund L.P. filed an amended Schedule 13G with the SEC (accession 0000921895-26-003172) updating its ownership stake in Crescent Biopharma, Inc. The filing signals a change in the fund's passive position in the clinical-stage biotech, though the amendment did not disclose a revised share count or percentage in the headline. Schedule 13G amendments are typically triggered when a holder's stake crosses the 5% threshold or moves by more than 5% of the class, making the filing a marker of shifting institutional interest. Investors will watch for the full filing details to confirm whether the fund added to or trimmed its position. Crescent Biopharma's share price reaction and any subsequent 13D or insider filings will indicate whether the change reflects conviction or routine portfolio rebalancing.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Biotechnology Value Fund L P, Crescent Biopharma, Inc.